ArticleVox sanguinis2025
Optimized pathogen reduction of double-dose platelets pooled from seven buffy coats using the TACSI® system.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimized pathogen reduction of double-dose platelets pooled from seven buffy coats using the TACSI® system.Vox sanguinis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPathogen reduction technologies (PRTs) can enhance platelet safety by mitigating pathogenic contamination risks. This study describes, for the first time, the in vitro platelet quality and function assessment of whole blood-derived double-dose (DD) pools, prepared using seven buffy coats (BCs) pooled on the Terumo Automated Centrifuge & Separator Integration (TACSI)® system and pathogen-reduced (PR) with the INTERCEPT™ Blood System (IBS). MATERIALS AND
methodsDD platelet pools were prepared by pooling seven ABO-identical BCs with 280 mL of additive solution platelet additive solution E using the TACSI® system. Process optimization ensured compliance with the European Directorate for the Quality of Medicines (EDQM) guidelines and IBS entry specifications. Units were split and either treated with IBS or left untreated, and stored agitated in INTERCEPT storage bags at 22°C for 8 days. Platelet quality was assessed at baseline and at Days 2, 6 and 8 using quality control tests and flow cytometry.
resultsAll units complied with EDQM specifications. Platelet concentration significantly decreased in IBS-treated platelets (p < 0.05). Both IBS-treated and untreated platelet units exhibited similar stability for mean platelet volume (MPV), gas exchange and pH. Higher glucose values were detected in IBS-treated platelets. CD62P expression and phosphatidylserine (PS) exposure significantly increased over storage in both groups, indicating comparable storage lesion and apoptosis, respectively. No differences were observed in the pro-coagulant activity of platelets, as both groups were responsive to agonist stimulation.
conclusionThe findings support the use of the IBS for pathogen reduction in larger platelet pools and highlight the system's effectiveness in maintaining platelet functionality for transfusion purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.